Literature DB >> 32283223

Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).

Farshad Abedi1, Ramin Rezaee2, Gholamreza Karimi3.   

Abstract

Entities:  

Year:  2020        PMID： 32283223     DOI： 10.1016/j.phrs.2020.104808

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN： 1043-6618            Impact factor:   7.658


× No keyword cloud information.
  13 in total

1.  Network analytics for drug repurposing in COVID-19.

Authors:  Nicoleta Siminea; Victor Popescu; Jose Angel Sanchez Martin; Daniela Florea; Georgiana Gavril; Ana-Maria Gheorghe; Corina Iţcuş; Krishna Kanhaiya; Octavian Pacioglu; Laura Lona Popa; Romica Trandafir; Maria Iris Tusa; Manuela Sidoroff; Mihaela Păun; Eugen Czeizler; Andrei Păun; Ion Petre
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

Review 2.  An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.

Authors:  Dragana Javorac; Lazar Grahovac; Luka Manić; Nikola Stojilković; Milena Anđelković; Zorica Bulat; Danijela Đukić-Ćosić; Marijana Curcic; Aleksandra Buha Djordjevic
Journal:  Food Chem Toxicol       Date:  2020-07-21       Impact factor: 6.023

3.  Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.

Authors:  Lorenzo A Calò; Giovanni Bertoldi; Paul A Davis
Journal:  Pharmacol Res       Date:  2020-05-13       Impact factor: 7.658

Review 4.  "A Chain Only as Strong as Its Weakest Link": An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19.

Authors:  Radu Crisan-Dabija; Cristina Alice Pavel; Iolanda Valentina Popa; Andrei Tarus; Alexandru Burlacu
Journal:  J Proteome Res       Date:  2020-09-17       Impact factor: 4.466

5.  Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality.

Authors:  Elnaz Vafadar Moradi; Ali Teimouri; Ramin Rezaee; Negar Morovatdar; Mahdi Foroughian; Parvaneh Layegh; Behrang Rezvani Kakhki; Seyed Reza Ahmadi Koupaei; Vahideh Ghorani
Journal:  Am J Emerg Med       Date:  2020-12-04       Impact factor: 2.469

6.  Identification of potentially anti-COVID-19 active drugs using the connectivity MAP.

Authors:  Raphaël Bonnet; Lee Mariault; Jean-François Peyron
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

7.  Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.

Authors:  Aliakbar Hasankhani; Abolfazl Bahrami; Negin Sheybani; Behzad Aria; Behzad Hemati; Farhang Fatehi; Hamid Ghaem Maghami Farahani; Ghazaleh Javanmard; Mahsa Rezaee; John P Kastelic; Herman W Barkema
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

Review 8.  Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.

Authors:  Sajad Fakhri; Zeinab Nouri; Seyed Zachariah Moradi; Esra Küpeli Akkol; Sana Piri; Eduardo Sobarzo-Sánchez; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

9.  Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Authors:  Katarina Baralić; Dragica Jorgovanović; Katarina Živančević; Evica Antonijević Miljaković; Biljana Antonijević; Aleksandra Buha Djordjevic; Marijana Ćurčić; Danijela Đukić-Ćosić
Journal:  Toxicol Appl Pharmacol       Date:  2020-09-11       Impact factor: 4.219

Review 10.  Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?

Authors:  Ahmed S Gouda; Bruno Mégarbane
Journal:  Drug Dev Res       Date:  2020-08-05       Impact factor: 5.004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.